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More than 1700 mutations in the low density lipoprotein receptor (LDLR) gene have been found to
cause familial hypercholesterolemia (FH). These are commonly divided into ﬁve classes based upon
their effects on the structure and function of the LDLR. However, little is known about the mecha-
nism by which mutations in the transmembrane domain of the LDLR gene cause FH. We have stud-
ied how the transmembrane mutation G805R affects the function of the LDLR. Based upon Western
blot analyses of transfected HepG2 cells, mutation G805R reduced the amounts of the 120 kDa pre-
cursor LDLR in the endoplasmic reticulum. This led to reduced amounts of the mature 160 kDa LDLR
at the cell surface. However, signiﬁcant amounts of a secreted 140 kDa G805R-LDLR ectodomain
fragment was observed in the culture media. Treatment of the cells with the metalloproteinase
inhibitor batimastat largely restored the amounts of the 120 and 160 kDa forms in cell lysates,
and prevented secretion of the 140 kDa ectodomain fragment. Together, these data indicate that a
metalloproteinase cleaved the ectodomain of the 120 kDa precursor G805R-LDLR in the endoplasmic
reticulum. It was the presence of the polar Arg805 and not the lack of Gly805 which led to ectodomain
cleavage. Arg805 also prevented c-secretase cleavage within the transmembrane domain. It is con-
ceivable that introducing a charged residue within the hydrophobic membrane lipid bilayer, results
in less efﬁcient incorporation of the 120 kDa G805R-LDLR in the endoplasmic reticulum membrane
and makes it a substrate for metalloproteinase cleavage.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The low density lipoprotein receptor (LDLR) binds low density
lipoprotein (LDL) at the cell surface and internalizes LDL by recep-
tor-mediated endocytosis [1]. Mutations in the LDLR gene which
lead to defective LDLRs and disrupted clearance of LDL, cause
familial hypercholesterolemia [1]. Typically, familial hypercholes-
terolemia heterozygotes have plasma LDL cholesterol levels in
the range of 6–11 mmol/l, whereas homozygotes have plasma
LDL cholesterol levels of approximately 20 mmol/l [1].The LDLR is synthesized as a 860 amino acid protein. After the
21 amino acid signal peptide has been cleaved off, the mature
839 amino acid LDLR is inserted in the endoplasmic reticulum
(ER) membrane and the ectodomain undergoes folding and glyco-
sylation in the ER [1]. The properly folded LDLR exits the ER and the
N-linked sugars are modiﬁed and the O-linked sugars are elon-
gated in the Golgi apparatus. This makes the apparent molecular
weight increase from 120 to 160 kDa [2]. After transport to the cell
membrane, the LDLR becomes concentrated in clathrin-coated pits
[3].
The LDLR has ﬁve functional domains [4]. The N-terminal li-
gand-binding domain consists of seven repeats of approximately
40 amino acids each. The next domain of approximately 400 amino
acids has a high degree of homology with the precursor for the epi-
dermal growth factor and contains a 280 amino acid b-propeller.
The third domain consists of 58 amino acids immediately
outside the cell membrane and is enriched in O-linked sugars.
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residue cytoplasmic domain contains the motifs required for con-
centrating the LDLR in clathrin-coated pits.
More than 1700 different mutations in the LDLR gene (www.u-
cl.ac.uk/ldlr) have been found to cause familial hypercholesterol-
emia and these may be classiﬁed into ﬁve classes based on their
effects on the LDLR [5]. Class 1 mutations prevent the synthesis
of immunodetectable LDLR. Class 2 mutations result in mutant
LDLRs which are completely (Class 2a) or partially (Class 2b) re-
tained in the ER. Class 3 mutations result in mutant LDLRs which
are incorporated in the cell membrane, but are defective in binding
LDL. Class 4 mutations result in mutant LDLRs which fail to concen-
trate in clathrin-coated pits. Class 5 mutations result in mutant
LDLRs which fail to release LDL in the endosome, leading to intra-
cellular degradation of the mutant LDLR. A suggested additional
class of mutations results in mutant LDLRs which fail to undergo
basolateral sorting in polarized cells [6].
The transmembrane domain of the LDLR is encoded by exon 16
and the 50 part of exon 17 [7] and ﬁve of the reported mutations in
this domain are missense mutations (www.ucl.ac.uk/ldlr). How-
ever, the mechanism by which mutations in this part of the gene
affect the function of the LDLR, has not been characterized. In this
study we have performed a series of studies to determine the
mechanism by which mutation G805R (c.2413G > A, Ref. seq.:
NM_000527.4) [8] in exon 17 of the LDLR gene causes familial
hypercholesterolemia.2. Results
2.1. Segregation analysis and bioinformatics analysis of mutation
G805R
Mutation G805R is a rare mutation in Norway. Only two of a to-
tal of 1850 unrelated patients provided with a molecular genetic
diagnosis of familial hypercholesterolemia, carry mutation
G805R. Segregation analysis among family members of one of
the index patients revealed that mutation G805R segregated with
hypercholesterolemia through 14 meioses (Supplementary
Fig. S1). The probability that this co-segregation occurred by
chance is (1/2)14 = 0.006%. Mutation G805R was predicted to be
pathogenic by the software programs PolyPhen2 (Score: ‘‘Probably
Damaging’’), SIFT (Score: ‘‘Not Tolerated’’) and Mutation Taster
(Score: ‘‘Disease Causing’’). A multiple sequence alignment of the
human LDLR (residues 764–839) and orthologs from 18 mammals
and 8 additional vertebrate species found by searching the UniProt
[9] and Ensembl [10] databases, is shown in Fig. 1. This alignment
shows Gly805 to be highly conserved and there is a complete lack of
residues with charged side chains in the transmembrane domain.
Together, these data indicate that mutation G805R is pathogenic.
The alignment also shows poor residue conservation in the ectodo-
main and in the transmembrane domain, but the latter is strongly
enriched in hydrophobic residues. Three conserved positively
charged residues of the cytoplasmic domain (Lys811, Arg814, and
Lys816 in the human LDLR, Fig. 1) appear to be necessary for insert-
ing the receptor with correct topology in the membrane, according
to the positive-inside rule [11].2.2. Characteristics of G805R-LDLR as determined by Western blot
analysis
To determine how mutation G805R affects the 120 kDa precur-
sor LDLR in the endoplasmic reticulum and/or the 160 kDa mature
LDLR at the cell surface, HepG2 cells were transiently transfected
with the G805R-LDLR plasmid. Because the wild-type (WT) LDLR
has been found to undergo c-secretase cleavage within the trans-membrane domain [12], the cells were cultured in the presence
or absence of the c-secretase inhibitor N-(N-(3,5-diﬂuorophenace-
tyl)-L-alanyl)-S-phenylglycine t-butyl ester (DAPT) to study
whether mutation G805R affects c-secretase cleavage. c-Secretase
cleavage of the WT-LDLR is preceded by ectodomain cleavage to
generate a residual C-terminal 17 kDa LDLR fragment, which is
acted upon by c-secretase to release the cytoplasmic domain
[12]. The released cytoplasmic domain is unstable and has a short
half-life which is typical of cytoplasmic domains released as part of
regulated intramembrane proteolysis [13,14]. Thus, it is predomi-
nantly in the presence of DAPT which inhibits c-secretase cleavage,
that a 17 kDa C-terminal cleavage fragment of the LDLR can be de-
tected by Western blot analysis [12].
Cell lysates of transfected HepG2 cells were subjected to
Western blot analysis using an antibody against the C-terminal
HA-tag. This antibody detects the 120 kDa precursor LDLR, the
160 kDa mature LDLR and a 17 kDa C-terminal cleavage fragment
(Fig. 2). HepG2 cells transfected with the G805R-LDLR plasmid
had markedly lower amounts of both the 120 kDa and the
160 kDa LDLR forms as compared to cells transfected with the
WT-LDLR plasmid, of 21% (±5) and 25% (±6), respectively. However,
the relative intensities of the bands representing the two LDLR
forms, were similar to that of the WT-LDLR (Fig. 2). Because muta-
tion G805R caused reduced amounts of both the precursor 120 kDa
and mature 160 kDa G805R-LDLR and not a selective reduction of
the mature 160 kDa form, it appears that this mutation primarily
reduced the amount of the precursor form which led to reduced
amounts of the mature form at the cell surface. Reduced amounts
of the cell-surface G805R-LDLR were also demonstrated by confo-
cal laser-scanning microscopy (Supplementary Fig. S2).
When HepG2 cells transfected with the WT-LDLR plasmid were
cultured in the absence of DAPT, virtually no 17 kDa C-terminal
fragment was observed for the WT-LDLR (Fig. 2). However, for
the G805R-LDLR a distinct band representing the 17 kDa C-terminal
fragment was observed in the absence of DAPT and apparently no
increased intensity of this band was observed in the presence of
DAPT (Fig. 2). These ﬁndings indicate that mutation G805R by
mimicking the effect of DAPT, prevents c-secretase cleavage within
the transmembrane domain.
2.3. Role of Gly805
To determine whether the reduced amounts of both the precur-
sor and mature G805R-LDLR were due to the lack of Gly805 or to the
presence of Arg805, the effect of mutations G805A and G805L on the
amounts of LDLRs were studied. As determined by Western blot
analysis of lysates from HepG2 cells transiently transfected with
the G805A-LDLR plasmid or the G805L-LDLR plasmid, the amounts
of the respective 120 kDa precursor LDLRs and the 160 kDa mature
LDLRs were similar to that of the WT-LDLR (Fig. 2). Moreover, as
determined by the increased amount of the respective 17 kDa
C-terminal LDLR fragments in the presence of DAPT, these two mu-
tant LDLRs were subjected to c-secretase cleavage similarly to that
of theWT-LDLR (Fig. 2). Thus, it is the presence of Arg805 within the
transmembrane domain which reduces the amounts of the
120 kDa precursor form and prevents c-secretase cleavage within
the transmembrane domain.
2.4. Effect of helix-destabilizing residues on c-secretase cleavage
c-Secretase cleavage of transmembrane alpha helices rely on
helix-destabilizing residues such as glycine, proline and serine, to
promote local unfolding within the alpha helix [15]. To study the
role of the highly conserved residues Pro795 and Gly805, as well as
Ser791 within the transmembrane domain of the LDLR (Fig. 1),
HepG2 cells were transiently transfected with mutant LDLR
Fig. 1. The LDLR transmembrane domain is devoid of residues with charged side chains. Multiple sequence alignment of the human LDLR (residues 764–839) and 29
vertebrate homologs shows a complete lack of charged residues in the transmembrane alpha helix passing through the membrane lipid bilayer. In the cartoon at the top, non-
polar-aliphatic and aromatic residues are indicated by blue circles, the highly conserved Pro795 and Gly805 by black circles, basic residues by red circles, and polar, neutral
residues by green circles. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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helix-stabilizing residue leucine. c-Secretase cleavage was mea-
sured as the ability of DAPT to increase the amount of the 17 kDa
C-terminal fragment. By transfecting plasmids containing one or
more mutations as indicated in Fig. 3, it was evident that mutating
individual residues only slightly reduced c-secretase cleavage,
whereas mutating the two highly conserved Pro795 and Gly805
almost completely reduced c-secretase cleavage. Mutating all
three residues appeared to completely prevent c-secretase cleav-
age. Thus, helix-destabilizing residues are important for c-secre-
tase cleavage of the transmembrane domain of the LDLR.
2.5. G805R-LDLR does not undergo proteasomal degradation
One mechanism for degradation of mutant proteins in the ER, is
ER-associated degradation which involves ubiquitination of the
cytoplasmic domain and subsequent proteasomal degradation
[16]. To study whether the low amount of the precursor G805R-
LDLR was due to proteasomal degradation, transfected HepG2 cells
were cultured in the presence or absence of the proteasome inhib-
itor lactacystine. Whereas, lactacystine increased the amounts of
the precursor and mature forms of the WT-LDLR by 61% (±10)and 18% (±16), which is consistent with previous reports [12,17],
lactacystine increased the amount of the precursor G805R-LDLR
by 13% (±23) and reduced the amount of the mature G805R-LDLR
by 21% (±19) (Fig. 4). Thus, the low amounts of G805R-LDLR in cell
lysates were apparently not due to proteasomal degradation of the
precursor form of G805R-LDLR.
2.6. The ectodomain of G805R-LDLR is cleaved by a metalloproteinase
In the culture medium of HepG2 cells transfected with the WT-
LDLR plasmid, a 140 kDa N-terminal degradation product caused
by ectodomain cleavage close to the cell membrane, can be ob-
served (Fig. 5). When the cells were cultured in the presence of
batimastat which inhibits a broad spectrum of metalloproteinases,
no 140 kDa fragment was found in the culture medium (Fig. 5).
These data are consistent with previous ﬁndings that metallopro-
teinase inhibitors prevent shedding of the 140 kDa ectodomain
fragment at the cell surface [18]. Moreover, in the medium of cells
transfected with the WT-LDLR plasmid, a 28 kDa fragment was ob-
served (Fig. 5). This fragment represents the ligand-binding repeats
1–4 which is cleaved off from the 160 kDa mature LDLR at the cell
surface [19]. The 140 kDa ectodomain fragment was also observed
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Fig. 2. Effect of mutation G805R on the amount of precursor and mature G805R-
LDLR. HepG2 cells were transiently transfected with the WT-LDLR plasmid or LDLR
plasmids containing mutations G805R, G805A or G805L. The cells were cultured in
the presence or absence of the c-secretase inhibitor DAPT (10 lM). Cell lysates were
subjected to Western blot analysis using an antibody against the C-terminal HA tag.
The 160 kDa mature LDLR, the 120 kDa precursor LDLR and a C-terminal 17 kDa
cleavage fragment are indicated. Beta-tubulin was used as a loading control. One
representative of three separate experiments is shown.
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Fig. 4. Effect of lactacystine on the amount of G805R-LDLR. HepG2 cells were
transiently transfected with theWT-LDLR or the G805R-LDLR plasmids and the cells
were cultured in the presence or absence of proteasome inhibitor lactacystine
(10 lM). Cell lysates were subjected to Western blot analysis using an antibody
against the C-terminal HA tag. The 160 kDa mature LDLR, the 120 kDa precursor
LDLR and a C-terminal 17 kDa cleavage fragment are indicated. Beta-tubulin was
used as a loading control. One representative of three separate experiments is
shown.
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but not when the cells were cultured in the presence of batimastat
(Fig. 5). Thus, also G805R-LDLR is subjected to metalloproteinase
cleavage.
Batimastat also affected the amounts of the LDLR in cell lysates.
However, the effect of batimastat on G805R-LDLR was different
from that on the WT-LDLR (Fig. 5). Whereas, batimastat increased
the amounts of the 120 and 160 kDa forms of the WT-LDLR by 12%
(±5) and 30% (±13), respectively, it markedly increased the
amounts of the 120 and 160 kDa forms of the G805R-LDLR by
82% (±30) and 142% (±47), respectively (Fig. 5). Moreover, batimas-
tat markedly reduced the amount of the residual 17 kDa C-termi-
nal G805R-LDLR cleavage fragment by 86% (±8) (Fig. 5). Together,
these data indicate that the reduced amounts of the 120 and
160 kDa forms of G805R-LDLR were caused by ectodomain cleav-
age of the 120 kDa form by a metalloproteinase.:7
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Fig. 3. Effect of mutating the alpha helix-destabilizing residues Ser791, Pro795 and Gly805 o
plasmid or plasmids containing one or more of the mutations S791L, P795L and G805R,
inhibitor DAPT (10 lM). Cell lysates were subjected to Western blot analysis using an
precursor LDLR and a C-terminal 17 kDa cleavage fragment are indicated. Beta-tubulin
shown.Such a metalloproteinase-induced ectodomain cleavage could
have taken place at the cell membrane, but this could not explain
the reduced amounts of the 120 kDa precursor G805R-LDLR
located in the ER. Thus, it is likely that metalloproteinase cleavage
of G805R-LDLR predominantly takes place in the ER. The cleaved
ectodomain is then released into the ER lumen for subsequent
transport through the secretory pathway to appear in the media
of transfected cells as a 140 kDa fragment after modiﬁcation of
sugars in the Golgi apparatus. Such an ectodomain cleavage of
the G805R-LDLR in the ER and subsequent secretion of the released
ectodomain, is reminiscent of that of transmembrane proteins
undergoing rhomboid cleavage in the ER [20]. Thus, whereas sim-
ilar amounts of the 140 kDa ectodomain fragment due to metallo-
proteinase cleavage is found in the culture media from cells
expressing the WT-LDLR or the G805R-LDLR (Fig. 5), the underly-
ing mechanism appears to be different. The WT-LDLR is predomi-
nantly cleaved at the cell surface, whereas the G805R-LDLR is
predominantly cleaved in the ER.
2.7. Functionality of the G805R-LDLR at the cell membrane
As determined by Western blot analysis, a proportion of the
120 kDa G805R-LDLR escaped metalloproteinase cleavage to gen-
erate a mature 160 kDa G805R-LDLR located at the cell surface
(Fig. 2 and Supplementary Fig. S2). Studies were therefore under-/
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n c-secretase cleavage. HepG2 cells were transiently transfected with the WT-LDLR
as indicated. The cells were cultured in the presence or absence of the c-secretase
antibody against the C-terminal HA tag. The 160 kDa mature LDLR, the 120 kDa
was used as a loading control. One representative of three separate experiments is
WT-LDLR G805R
- + - + 
Medium
160 kDa
120 kDa
140 kDa
28 kDa
Batimastat
17 kDa
Lysate
Fig. 5. Effect of batimastat on the amount of G805R-LDLR. HepG2 cells were
transiently transfected with the WT-LDLR or G805R-LDLR plasmids and the cells
were cultured in the presence or absence of the metalloproteinase inhibitor
batimastat (10 lM). Lysates and culture media were subjected to Western blot
analysis. An antibody against the C-terminal HA tag was used to probe the lysates
and an antibody against the ligand-binding domain was used to probe the media. In
the media a 140 kDa ectdomain fragment and a 28 kDa fragment containing ligand-
binding repeats 1–4 are shown. In the lysates the 160 kDa mature LDLR, the
120 kDa precursor LDLR and a C-terminal 17 kDa cleavage fragment are indicated.
One representative of three separate experiments is shown.
Time without tet 
[h] 0 16 24 40 48
No 
tet
WT-LDLR
G805R-LDLR
Fig. 7. Stability of G805R-LDLR. CHO T-REx cells stably transfected with the WT-
LDLR plasmid or the G805R-LDLR plasmid were incubated with tetracycline (tet)
(1 lg/ml) to induce the expression of the transgenes. The media were removed and
replaced with media without tetracycline and cultured for the indicated time
intervals (h: hours), before Western blot analysis of cell lysates was performed
using an antibody against the ligand-binding domain of the LDLR. Western blot of
cells cultured in the absence of tetracycline to induce gene expression (No tet) was
used as a control. One representative of three separate experiments is shown.
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the cell surface. CHO T-REx cells stably transfected with the
G805R-LDLR plasmid were used to determine the kinetics of inter-
nalization of DiD-labelled LDL. As can be seen from Fig. 6, cells
expressing G805R-LDLR internalized DiD–LDL with high afﬁnity
and saturation kinetics similarly to that of cells expressing the
WT-LDLR. This ﬁnding indicates that the proportion of G805R-0
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Fig. 6. Internalization of DiD–LDL by the cell-surface G805R-LDLR. CHO T-REx cells
stably transfected with the WT-LDLR plasmid or the G805R-LDLR plasmid were
incubated with tetracycline (1 lg/ml) to induce the expression of the transgenes,
and incubated with increasing concentrations of DiD–LDL for 2 h at 37 C. The
amount of internalized DiD–LDL was determined by ﬂow cytometry. The amount of
ﬂuorescence detected after incubation with 150 lg/ml of DiD–LDL was given an
arbitrary value of 1.0 for cells transfected with each of the plasmids. Mean (±SD)
values from three separate experiments are shown. SD for the WT-LDLR is shown as
upward symbols and SD for the G805R-LDLR is shown as downward symbols.LDLR which escapes metalloproteinase cleavage, functions
normally.
Studies were also performed to determine the stability of the
mature 160 kDa G805R-LDLR at the cell surface. This was done
by measuring the decay of the 160 kDa G805R-LDLR after removal
of the transcription inducer tetracycline. These analyses revealed
that the 160 kDa G805R-LDLR was slightly less stable than the
WT-LDLR with half-lives of 13 and 16 h, respectively (Fig. 7, Quan-
tiﬁed in Supplementary Fig. S3). A tendency for reduced stability of
the G805R-LDLR at the cell surface, could possibly result from an
increased propensity of the 160 kDa G805R-LDLR to undergo
metalloproteinase cleavage also at the cell surface.
3. Discussion
In this study we have characterized the mechanism by which
mutation G805R in the transmembrane domain of the LDLR gene
causes familial hypercholesterolemia. As determined by Western
blot analysis of lysates from transfected HepG2 cells, there were
reduced amounts of the 120 kDa precursor G805R-LDLR and conse-
quently reduced amounts of the 160 kDa mature cell-surface
G805R-LDLR. The underlying mechanism for the reduced amounts
of the 120 kDa precursor G805R-LDLR appeared to be that the ecto-
domain of G805R-LDLR was cleaved by a metalloproteinase in the
ER. This cleavage generated an ectodomain fragment released into
the ER lumen which appeared as a secreted 140 kDa fragment in
the culture medium. It was the presence of Arg805 and not the lack
of Gly805 which promoted metalloproteinase cleavage. Moreover,
the proportion of G805R-LDLR which escaped ectodomain cleavage
and was inserted in the cell membrane, functioned normally. Thus,
mutation G805R causes familial hypercholesterolemia by reducing
the number of cell-surface LDLRs without affecting their function.
The approximately 20–22 residues of the transmembrane alpha
helix of single-pass membrane proteins are generally strongly en-
riched in aliphatic and other hydrophobic residues which stabilize
the structure in the nonpolar interior of the membrane lipid
bilayer. The sequence alignment in Fig. 1 shows relatively poor res-
idue conservation in the LDLR transmembrane domain in verte-
brates. However, there is clearly a selection against mutations
that introduce polar and in particular charged residues in the
transmembrane domain, with not one single charged residue
among the more than 600 membrane-interacting residues. Thus,
it is likely that mutation G805R results in a mutant LDLR that is
less efﬁciently inserted into the ER membrane due to the energetic
cost of dehydrating and transferring the charged guanidinium
group of arginine into the nonpolar lipid bilayer. However, exper-
imental studies have demonstrated that the energetic cost of
326 T.B. Strøm et al. / FEBS Open Bio 4 (2014) 321–327inserting arginine residues in transmembrane helices, is rather low
due to the arginine side chain ‘‘snorkelling’’ out of the lipid bilayer
core [21]. Thus, a single arginine residue in a transmembrane alpha
helix may lead to signiﬁcant tilting of the helix as well as bilayer
thinning as the guanidinium group is lifted towards the bilayer
surface [22]. These changes may make the G805R-LDLR a substrate
for metalloproteinase cleavage.
A likely metalloproteinase to act on G805R-LDLR in the ER is ‘‘a
disintegrin and metalloproteinase’’ (ADAM) 17 which is induced by
phorbol 12-myristate 13-acetate. ADAM17 is inhibited by batimas-
tat and has been found to cause ectodomain shedding of a large
number of transmembrane proteins [23]. ADAM17 has also been
implicated by Begg et al. [19] as being the enzyme which cleaves
the ectodomain of the WT-LDLR at the cell surface. However,
silencing ADAM17 by the use of si-RNA caused only a marginal in-
crease in the amount of the 120 kDa G805R-LDLR (data not
shown). This indicates that also other metalloproteinases are in-
volved. Also rhomboids such as the ER-resident rhomboid protease
RHBDL4 have been shown to cleave transmembrane domains with
helix-destabilizing residues [20,24,25].
Usually, ectodomain cleavage by a metalloproteinase as part of
regulated intramembrane proteolysis, is followed by c-secretase
cleavage within the transmembrane domain to release the cyto-
plasmic domain [13]. However, as determined by our experiments
where the transfected cells were cultured in the presence or
absence of the c-secretase inhibitor DAPT, mutation G805R pre-
vented subsequent c-secretase cleavage within the transmem-
brane domain. When Gly805 was substituted with Leu805 or
Ala805, the transmembrane domain was subjected to c-secretase
cleavage similarly to that of the WT-LDLR. Thus, it was the pres-
ence of Arg805 within the transmembrane domain which prevented
c-secretase cleavage.
The near absolute conservation of residues Pro795 and Gly805 in
the LDLR is a strong indication of the functional importance of
these residues. They may possibly reduce the rigidity of the trans-
membrane helix and allowmembrane-bound proteinases access to
the LDLR peptide backbone. Proline is known as a helix breaker
[26], while the lack of a side chain at glycine makes the conforma-
tion of the alpha helix backbone less stable at this residue. Our data
show that these conserved residues are important for c-secretase
cleavage of the transmembrane alpha helix. However, whether
c-secretase cleavage of the LDLR plays any physiological role,
remains to be determined.
There are other examples of monogenic diseases caused by
mutations which lead to charged residues being introduced in
the transmembrane domain of the respective proteins. One such
example is mutation G308R within the transmembrane domain
of ﬁbroblast growth factor receptor 3 which accounts for the
underlying mutation in 97% of achondroplasia cases [27]. Another
example is mutation G163R in myelin protein zero which causes
Charcot–Marie–Tooth disease Type 1b [28]. Such mutations which
introduce hydrophilic residues within the hydrophobic lipid
bilayer, could cause genetic diseases by affecting c-secretase cleav-
age and prevent subsequent release of cytoplasmic domains for
intracellular signalling, or by causing ectodomain shedding leading
to reduced amounts of functioning protein.
In conclusion, the mechanism by which mutation G805R causes
familial hypercholesterolemia, is through ectodomain cleavage of
G805R-LDLR in the ER by a metalloproteinase. Because this mech-
anism is different from those underlying the previously reported
classes of mutations in the LDLR gene, mutation G805R should
be considered a member of a novel class of mutations causing
familial hypercholesterolemia. Whether the other naturally occur-
ring mutations in the transmembrane domain of the LDLR gene
also induce ectodomain cleavage of the mutant LDLR, remains to
be determined.4. Materials and methods
4.1. Reagents
DAPT and lactacystine were purchased from Sigma–Aldrich
Corp. (St. Louis, MO). Batimastat was from Calbiochem (Darmstadt,
Germany). All other reagents were standard laboratory reagents.
4.2. Cell cultures
CHO T-REx cells (Invitrogen, Carlsbad, CA) express a tetracycline
repressor which enables tetracycline-induced expression of genes
cloned into plasmids containing the tetracycline operator 2 ele-
ment. These cells were maintained in Ham’s F-12 medium (PAA
Laboratories GmbH, Pasching, Austria) supplemented with 10% fe-
tal bovine serum, 2 mM L-glutamine, 50 U/ml penicillin, 50 lg/ml
streptomycin, 100 lg/ml blasticidine and 100 lg/ml zeocin. HepG2
cells (European Collection of Cell Cultures, Wiltshire, UK) were
maintained in Modiﬁed Eagle’s medium (PAA Laboratories GmbH,
Pasching, Austria) containing 10% fetal bovine serum, 2 mM L-glu-
tamine, 50 U/ml penicillin, 50 lg/ml streptomycin and non-essen-
tial amino acids, and were grown in collagen-coated plates (BD
Biosciences, San Jose, CA).
4.3. Plasmids and transfections
Generation of plasmids pcDNA4-WT-LDLR and pcDNA4-WT-
LDLR-HA, encoding the LDLR without or with a C-terminal HA
tag, has previously been described [29]. pcDNA4-WT-LDLR was
used as template to generate the mutant G805R-LDLR. The
pcDNA4-WT-LDLR-HA plasmid was used as a template to generate
G805R-LDLR-HA, G805L-LDLR-HA, G805A-LDLR-HA, S791L-LDLR-
HA and P795L-LDLR-HA. Mutageneses were carried out using
QuickChange II XL Mutagenesis Kit (Agilent Technologies, Santa
Clara, CA) according to the manufacturer’s instructions. The oligo-
nucleotide sequences used for mutageneses are listed in Supple-
mentary Table S1. HepG2 cells were transiently transfected using
FuGENE HD (Roche Diagnostics GmbH, Mannheim, Germany)
according to the manufacturer’s instructions. Stable transfections
of CHO T-REx cells were performed as previously described [30].
The integrity of the plasmids and the transgenes of stably transfec-
ted cell lines was conﬁrmed by DNA sequencing.
4.4. Western blot analyses
Western blot analyses of cell lysates and culture media were
carried out as previously described [31]. Brieﬂy, 24 h after transfec-
tion culture media and cell lysates were obtained and run on 4–
20% Tris–HCl Criterion Precast Gels (Bio-Rad, Hercules, CA) and
blotted onto Immuno-Blot PVDF Membranes (Bio-Rad, Hercules,
CA). To detect the LDLR, the membranes were immunostained with
a rabbit anti-HA antibody (Invitrogen, Carlsbad, CA) or a rabbit
polyclonal anti-LDLR antibody which detects the linker region be-
tween ligand-binding repeats 4 and 5 (Fitzgerald Industries Inter-
national, Concord, MA). Anti b-tubulin antibody was from
USBiological (Salem, MA).
4.5. Flow cytometry
LDL (density 1.019–1.063 g/ml) was isolated by ultracentrifuga-
tion of human serum and labeled with ﬂuorescent 1,10-dioctade-
cyl-3,3,30,30-tetramethylindodicarbocyanine perchlorate (DiD)
(Sigma–Aldrich Corp., St. Louis, MO) as described by Pitas et al.
[32]. A FACS Canto ﬂow cytometer (BD Biosciences, San Diego,
CA) was used to determine the amount of internalized DiD–LDL
T.B. Strøm et al. / FEBS Open Bio 4 (2014) 321–327 327as previously described [33]. Brieﬂy, stably transfected CHO T-REx
were seeded out at 200,000 cells per well in 6-well plates, and
incubated over night in culture media containing tetracycline
(1 lg/ml) to induce gene expression. The cells were then incubated
with DiD–LDL for 2 h at 37 C before the amount of internalized
DiD–LDL was measured by ﬂow cytometry.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.fob.2014.03.007.
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